Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
World J Biol Psychiatry. 2012 Dec;13(8):627-32. doi: 10.3109/15622975.2011.599861. Epub 2011 Sep 22.
To determine whether a molecular signature is present in blood of patients with psychiatric disorders before manifestation of symptoms.
Multiplex immunoassay analyses were carried out using serum obtained from two case-control studies of schizophrenia (n = 75) and bipolar disorder (n = 110) patients and their matched controls. The samples were drawn within 1 month before estimated onset of illness.
This led to identification of 20 molecules which were altered in pre-schizophrenia and 14 molecules in pre-bipolar disorder subjects compared to controls. Only two of these molecular changes were identical in both data sets and predictive testing confirmed that the biomarker signatures for pre-schizophrenia and pre-bipolar disorder were dissimilar.
The present results suggest that there are distinct serum alterations that occur before clinical manifestation of schizophrenia and bipolar disorder. These findings could lead to development of diagnostic tests to help clinical psychiatrists identify and classify vulnerable patients early in the disease process, allowing for earlier and more effective therapeutic intervention.
确定精神疾病患者在出现症状之前的血液中是否存在分子特征。
使用来自精神分裂症(n = 75)和双相情感障碍(n = 110)患者及其匹配对照的两项病例对照研究获得的血清进行多重免疫分析。这些样本是在预计发病前 1 个月内抽取的。
这导致鉴定出与对照组相比,在精神分裂症前患者中改变的 20 种分子和在双相情感障碍前患者中改变的 14 种分子。在这两个数据集中共有的分子变化只有两个,预测性测试证实,精神分裂症前和双相情感障碍前的生物标志物特征是不同的。
目前的结果表明,在精神分裂症和双相情感障碍出现临床症状之前,存在明显的血清改变。这些发现可能导致开发诊断测试,以帮助临床精神科医生在疾病过程的早期识别和分类易受影响的患者,从而更早、更有效地进行治疗干预。